样式: 排序: IF: - GO 导出 标记为已读
-
The yield of routine laboratory examination in osteoporosis evaluation in primary care Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-03-18 Thomas Merlijn, Karin M. A. Swart, Christy Niemeijer, Henriëtte E. van der Horst, Coen. J. Netelenbos, Petra J. M. Elders
-
Determination of the Combined Effects of Asian Herbal Medicine with Calcium and/or Vitamin D Supplements on Bone Mineral Density in Primary Osteoporosis: A Systematic Review and Meta-Analysis Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-03-13 Hee-Joo Park, Min-Gyeong Kim, Young-Seo Yoo, Bo-Ram Lee, Yu-Jin Choi, Chang-Gue Son, Eun-Jung Lee
-
Associations between ultra-distal forearm bone mineral density and incident fracture in women Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-03-06 Kara L. Holloway-Kew, Amelia G. Betson, Kara B. Anderson, Mark A. Kotowicz, Julie A. Pasco
-
The incidence of subsequent contralateral hip fracture and factors associated with increased risk: the IMPACT Contralateral Fracture Study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-03-06 Robert S. Kay, Lucas Ho, Nick D. Clement, Andrew D. Duckworth, Andrew J. Hall
-
CT image-based biomarkers for opportunistic screening of osteoporotic fractures: a systematic review and meta-analysis Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-02-14 Anitha D. Praveen, Nico Sollmann, Thomas Baum, Stephen J. Ferguson, Helgason Benedikt
-
Physical performance and sarcopenia assessment in patients with a recent fracture visiting the Fracture Liaison Service Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-02-13 M. R. Schene, H. C. Willems, J. H. M. Driessen, L. Vranken, F. O. Lambers Heersprink, H. M. J. Janzing, R. Y. van der Velde, J. P. van den Bergh, C. E. Wyers
-
Prunes preserve cortical density and estimated strength of the tibia in a 12-month randomized controlled trial in postmenopausal women: The Prune Study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-02-13 Kristen J. Koltun, Nicole C. A. Strock, Connie Weaver, Hang Lee, Nancy I. Williams, Connie J. Rogers, Janhavi Damani, Mario G. Ferruzzi, Cindy H. Nakatsu, Mary Jane De Souza
-
Return on investment of fracture liaison services: a systematic review and analysis Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-02-01 L. Xu, T. Zhao, L. Perry, S.A. Frost, G.L. Di Tanna, S. Wang, M. Chen, G.S. Kolt, S. Jan, L. Si
-
An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-01-31 Kosuke Ebina, Yoshio Nagayama, Masafumi Kashii, Hideki Tsuboi, Gensuke Okamura, Akira Miyama, Yuki Etani, Takaaki Noguchi, Makoto Hirao, Taihei Miura, Yuji Fukuda, Takuya Kurihara, Ken Nakata, Seiji Okada
-
Vertebral fracture severity assessment on anteroposterior radiographs with a new semi-quantitative technique Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-01-31 W. Yu, W.-M. Guan, D. Hayashi, Q. Lin, M.-M. Du, W.-B. Xia, Y.-X.J. Wang, A. Guermazi
-
Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-01-23 Seongmin Jeon, Dongwoo Yu, Sungho Kim, Sang Woo Kim, Ikchan Jeon
-
Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2024-01-10 Miriam T. Y. Leung, Justin P. Turner, Clara Marquina, Jenni Ilomaki, Tim Tran, J. Simon Bell
-
Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and review Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-28 Kevin McCarroll, Donal Fitzpatrick, Margaret McCormack, Sabah Abdelfadil, Vivion Crowley, Rosaleen Lannon, Martin Healy
Background Parathyroid hormone (PTH) measurements can be falsely elevated due to the hormone binding to other molecules (macro-PTH) or immunoassay interference with heterophile, human anti-animal or other antibodies. This is rare but could lead to incorrect diagnosis, unnecessary investigations or avoidance of teriparatide treatment. We report a case of falsely high PTH levels due to assay interference
-
Higher risk of osteoporosis in adult-onset asthma than childhood-onset asthma: from genetic and prospective evidence Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-23 Weizhong Ding, Yong Huang, Guanghui Li, Yimin Dong, Xiaochen Li, Minglong Wu, Kehan Song, Feng Li
-
Effect of recreational cannabis use on bone mineral density: a systematic review Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-23 Luiz Alexandre Viana Magno, Diego Ribeiro Tameirão, Lucas Ferreira Alves, Nathalia Sernizon Guimarães
-
Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-08 Liqin Zhang, Weihong Wang, Liang Wen, Fenglin Xue, Jingyi Li, Yemei Qian
-
A prediction model of elderly hip fracture mortality including preoperative red cell distribution width constructed based on the random survival forest (RSF) and Cox risk ratio regression Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-07 Ying-feng Zhou, Jiao Wang, Xin-lin Wang, Shu-shu Song, Yue Bai, Jian-lin Li, Jing-yu Luo, Qi-qi Jin, Wei-cha Cai, Kai-ming Yuan, Jun Li
-
Obesity, diabetes and risk of bone fragility: How BMAT behavior is affected by metabolic disturbances and its influence on bone health Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-06 Gregório Corrêa Guimarães, João Bosco Costa Coelho, João Gabriel Oliveira Silva, Ana Carolina Chalfun de Sant’Ana, Cássia Alves Carrilho de Sá, Júlia Marques Moreno, Lívia Marçal Reis, Camila Souza de Oliveira Guimarães
-
A prediction model of elderly hip fracture mortality including preoperative red cell distribution width constructed based on the random survival forest (RSF) and Cox risk ratio regression Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-07 Ying-feng Zhou, Jiao Wang, Xin-lin Wang, Shu-shu Song, Yue Bai, Jian-lin Li, Jing-yu Luo, Qi-qi Jin, Wei-cha Cai, Kai-ming Yuan, Jun Li
-
Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-08 Liqin Zhang, Weihong Wang, Liang Wen, Fenglin Xue, Jingyi Li, Yemei Qian
-
Geographic variation in bone mineral density and prevalent fractures in the Canadian longitudinal study on aging Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-02 N. Hassanabadi, C. Berger, A. Papaioannou, A. M. Cheung, E. Rahme, W. D. Leslie, D. Goltzman, S. N. Morin
-
Association of clinicopathologic and molecular factors with the occurrence of positive margins in breast cancer. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-12-01 Anupama Praveen Kumar,Diego Vicente,Jianfang Liu,Praveen-Kumar Raj-Kumar,Brenda Deyarmin,Xiaoying Lin,Craig D Shriver,Hai Hu
PURPOSE To explore the association of clinicopathologic and molecular factors with the occurrence of positive margins after first surgery in breast cancer. METHODS The clinical and RNA-Seq data for 951 (75 positive and 876 negative margins) primary breast cancer patients from The Cancer Genome Atlas (TCGA) were used. The role of each clinicopathologic factor for margin prediction and also their impact
-
Effect of gender on the evolution of pain and quality of life after treatment of symptomatic vertebral fragility fractures Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-30 Pilar Peris, Jordi Blasco, Ana Monegal, Helena Florez, Núria Guañabens, Josep Lluis Carrasco
-
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-29 Erica L Mayer,Nabihah Tayob,Siyang Ren,Jennifer J Savoie,David R Spigel,Howard A Burris,Paula D Ryan,Lyndsay N Harris,Eric P Winer,Harold J Burstein
PURPOSE Metronomic chemotherapy has the potential to offer tumor control with reduced toxicity when compared to standard dose chemotherapy in patients with metastatic breast cancer. As metronomic chemotherapy may target the tumor microvasculature, it has the potential for synergistic effects with antiangiogenic agents such as the VEGF-A inhibitor bevacizumab. METHODS In this randomized phase II study
-
Hypophosphatasia: presentation and response to asfotase alfa Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-23 F. Alsarraf, D.S. Ali, K. Almonaei, H. Al-Alwani, A.A. Khan, M.L. Brandi
Summary Hypophosphatasia (HPP) is a rare bone disease with limited scientific evidence on the tolerability and safety of its novel treatment, Asfotase Alfa (AA). We report 7 HPP patients’ heterogenous presentations and the significant improvement in various clinical outcomes attained with AA shedding light on this highly effective and safe therapy. Introduction Hypophosphatasia (HPP) is a rare inherited
-
Systematic review and meta-analysis of preoperative predictors for early mortality following hip fracture surgery Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-24 Michael Bui, Wieke S. Nijmeijer, Johannes H. Hegeman, Annemieke Witteveen, Catharina G. M. Groothuis-Oudshoorn
-
"Enhancing survival outcomes through breast-conserving therapy in ipsilateral breast tumor recurrence: insights into metastasis and treatment strategies". Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-24 Kefah Mokbel,Munaser Alamoodi
-
Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-24 Deanna Blansky,Norin Ansari,Lucy Gao,Ethan S Sokol,Smruthy Sivakumar,Richard S P Huang,Maureen Pelletier,Mia Levy,Dean Pavlick,Natalie Danziger,Jeffrey S Ross,Maryam Lustberg,Mariya Rozenblit
PURPOSE Approximately 5% of breast cancers each year are diagnosed in young women < 40 years who tend to have worse clinical outcomes. We compared genomic alterations using comprehensive genomic profiling (CGP) of tumor tissue among very young women (< 30 years) and young women (30-39 years) compared to women ≥ 40 years at diagnosis. METHODS 2049 advanced breast cancer cases were submitted to Foundation
-
Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-20 Aliya A. Khan, Maria Luisa Brandi, Eric T. Rush, Dalal S. Ali, Hatim Al-Alwani, Khulod Almonaei, Farah Alsarraf, Severine Bacrot, Kathryn M. Dahir, Karel Dandurand, Chad Deal, Serge Livio Ferrari, Francesca Giusti, Gordon Guyatt, Erin Hatcher, Steven W. Ing, Muhammad Kassim Javaid, Sarah Khan, Roland Kocijan, Agnes Linglart, Iman M’Hiri, Francesca Marini, Mark E. Nunes, Cheryl Rockman-Greenberg, Christian
-
Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-20 Eric Rush, Maria Luisa Brandi, Aliya Khan, Dalal S. Ali, Hatim Al-Alwani, Khulod Almonaei, Farah Alsarraf, Severine Bacrot, Kathryn M. Dahir, Karel Dandurand, Chad Deal, Serge Livio Ferrari, Francesca Giusti, Gordon Guyatt, Erin Hatcher, Steven W. Ing, Muhammad Kassim Javaid, Sarah Khan, Roland Kocijan, E. Michael Lewiecki, Agnes Linglart, Iman M’Hiri, Francesca Marini, Mark E. Nunes, Cheryl Rockman-Greenberg
-
The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-20 Maria Luisa Brandi, Aliya A. Khan, Eric T. Rush, Dalal S. Ali, Hatim Al-Alwani, Khulod Almonaei, Farah Alsarraf, Severine Bacrot, Kathryn M. Dahir, Karel Dandurand, Chad Deal, Serge Livio Ferrari, Francesca Giusti, Gordon Guyatt, Erin Hatcher, Steven W. Ing, Muhammad Kassim Javaid, Sarah Khan, Roland Kocijan, E. Michael Lewiecki, Agnes Linglart, Iman M’Hiri, Francesca Marini, Mark E. Nunes, Cheryl
-
Deprescribing bisphosphonates for older adults with dementia: perspectives of caregivers Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-18 Joshua D. Niznik, Casey J. Kelley, Lauren Fasth, Cathleen Colón-Emeric, Carolyn T. Thorpe, Meredith A. Gilliam, Jennifer L. Lund, Laura C. Hanson
-
Patients’ preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-13 Charlotte Beaudart, Mitali Sharma, Patricia Clark, Saeko Fujiwara, Jonathan D. Adachi, Osvaldo D. Messina, Suzanne N. Morin, Lynn A. Kohlmeier, Caroline B. Sangan, Xavier Nogues, Griselda Adriana Cruz-Priego, Andrea Cavallo, Fiona Cooper, Jamie Grier, Carolyn Leckie, Diana Montiel-Ojeda, Alexandra Papaioannou, Nele Raskin, Leonardo Yurquina, Michelle Wall, Olivier Bruyère, Annelies Boonen, Elaine Dennison
-
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-15 Ryo Karakawa,Takaaki Konishi,Hidehiko Yoshimatsu,Yohei Hashimoto,Hiroki Matsui,Kiyohide Fushimi,Tomoyuki Yano,Hideo Yasunaga
BACKGROUND Although autologous reconstruction following breast cancer surgery is common, little is known about the association between preoperative body mass index (BMI) and short-term surgical outcomes. This study investigated the association between BMI and short-term surgical outcomes in autologous breast reconstruction using a nationwide Japanese inpatient database. METHODS We retrospectively identified
-
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-14 Sena Alaeikhanehshir,Renée S J M Schmitz,Alexandra W van den Belt-Dusebout,Frederieke H van Duijnhoven,Ellen Verschuur,Maartje van Seijen,Michael Schaapveld,Esther H Lips,Jelle Wesseling,
PURPOSE To assess the effects of contemporary treatment of ductal carcinoma in situ (DCIS) on the risk of developing an ipsilateral invasive breast cancer (iIBC) in the Dutch female population. METHODS Clinical data was obtained from the Netherlands Cancer Registry (NCR), a nationwide registry of all primary malignancies in the Netherlands integrated with the data from PALGA, the Dutch nationwide network
-
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-13 Celine Yeh,Mengxi Zhou,Neil Bapodra,Dawn Hershman,Edward Espinal,Marina Moran,Maria Rivero,Antonio Tito Fojo,Susan E Bates
PURPOSE There remains a need for novel therapies for patients with metastatic breast cancer (MBC). We explore the use of a novel biomarker of survival that could potentially expedite the testing of novel therapies. METHODS We applied a tumor regression-growth model to radiographic measurement data from 393 women with MBC enrolled in PALOMA-3 examining efficacy of palbociclib in disease that had progressed
-
Evaluation of costs, osteoporosis treatment, and re-fractures in German collaborative orthogeriatric care after fragility fractures Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-09 Claudia Konnopka, Gisela Büchele, Andrea Jaensch, Dietrich Rothenbacher, Clemens Becker, Kilian Rapp, Espen Henken, Hans-Helmut König
-
The joint effects of physical activity and sleep duration on risk of osteoporosis in Taiwanese adult population: The Taiwan Biobank Study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-10 Kun-Hui Chen, Chen-Ming Su, Wei-Ju Liu, Huey-En Tzeng, Chia-Lin Lee, Chun-Hao Tsai
-
Positive predictive value of axillary lymph node cortical thickness and nodal, clinical, and tumor characteristics in newly diagnosed breast cancer patients. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-10 Anne-Sophie T Loonis,Allyson L Chesebro,Camden P Bay,Leah H Portnow,Anna Weiss,Sona A Chikarmane,Catherine S Giess
PURPOSE Axillary lymph nodes (LNs) with cortical thickness > 3 mm have a higher likelihood of malignancy. To examine the positive predictive value (PPV) of axillary LN cortical thickness in newly diagnosed breast cancer patients, and nodal, clinical, and tumor characteristics associated with axillary LN metastasis. METHODS Retrospective review of axillary LN fine needle aspirations (FNAs) performed
-
LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-09 Helene Tietze, Veronika Pott, Nele Kanzelmeyer, Nima Memaran, Ulrich Baumann, Charlotte Mindermann, Adriana Suhlrie, Jens Drube, Anette Melk, Anibh M. Das, Dirk Schnabel, Dieter Haffner, Maren Leifheit-Nestler
-
The incremental risk of fragility fractures in aging men Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-08 A.R. Agarwal, O. Tarawneh, J.S. Cohen, A. Gu, K.F. Moseley, J.N. DeBritz, G.J. Golladay, S.C. Thakkar
-
Effect of educational intervention on preventing osteoporosis in postmenopausal women Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-08 S. Najafi, F. Mohammadkhah, M.M. Ebrahimi, P.A. Harsini, A. Khani Jeihooni
-
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-08 Diogo Martins-Branco,Marie Kassapian,Véronique Debien,Rafael Caparica,Daniel Eiger,Urania Dafni,Charitini Andriakopoulou,Sarra El-Abed,Susan L Ellard,Miguel Izquierdo,Malou Vicente,Saranya Chumsri,Martine Piccart-Gebhart,Alvaro Moreno-Aspitia,Ann Søegaard Knop,Janine Lombard,Evandro de Azambuja
PURPOSE To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC). METHODS ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant anti-HER2 treatment. Disease-free-survival (DFS), overall survival (OS), and time-to-distant recurrence (TTDR) were analyzed by ESA administration, with subgroup
-
Pre-operative bone quality deficits and risk of complications following spine fusion surgery among postmenopausal women Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-07 Alexander S. Dash, Emma Billings, Katelyn Vlastaris, Han Jo Kim, Matthew E. Cunningham, Joseph Raphael, Francis Lovecchio, John A. Carrino, Darren Lebl, Donald McMahon, Emily M. Stein
-
Individual and area level factors associated with the breast cancer diagnostic-treatment interval in Queensland, Australia. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-06 James D Retell,Jessica K Cameron,Joanne F Aitken,Philippa Youl,Chris Pyke,Jeff Dunn,Suzanne Chambers,Peter D Baade
BACKGROUND Delays to breast cancer treatment can lead to more aggressive and extensive treatments, increased expenses, increased psychological distress, and poorer survival. We explored the individual and area level factors associated with the interval between diagnosis and first treatment in a population-based cohort in Queensland, Australia. METHODS Data from 3216 Queensland women aged 20 to 79,
-
Forearm bone mineral density predicts screw loosening after lumbar fusion similar to lumbar Hounsfield unit value in patients with lumbar spondylolisthesis Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-03 Qian Chen, Zhen Tu, Youwei Ai, Wen Li, Jianwen Chen, Junfei Feng, Wei Deng, Ye Wang, Ping Jiang
-
Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-04 Lei Lei,Yuan Huang,Lei Shi,Weiwu Ye,Xianmei Lv,Lisha Ying,Xingfei Yu,Skye Hung-Chun Cheng,Yabing Zheng
PURPOSE Endocrine therapy is the anti-tumor therapy for human breast cancer but endocrine resistance was a major burden. It has been reported that Palbociclib and fulvestrant can be used in combination for the treatment of patients who are experiencing endocrine resistance. However, the underlying mechanism is unclear. In this study, we aimed to investigate the mechanism by which Palbocicilib affected
-
-
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-04 K K Rajan,C Boersma,M A Beek,T A Berendsen,J van der Starre-Gaal,M van 't Veer-Ten Kate,A B Francken,E M Noorda
PURPOSE In the treatment of breast cancer, neo-adjuvant chemotherapy is often used as systemic treatment followed by tumor excision. In this context, planning the operation with regard to excision margins relies on tumor size measured by MRI. The actual tumor size can be determined through pathologic evaluation. The aim of this study is to investigate the correlation and agreement between pre-operative
-
Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-04 Elizabeth D Kantor,Kelli O'Connell,Isaac J Ergas,Emily Valice,Janise M Roh,Jenna Bhimani,Narre Heon,Jennifer J Griggs,Jean Lee,Erin Ja Bowles,Donna R Rivera,Tatjana Kolevska,Elisa V Bandera,Lawrence H Kushi
PURPOSE Most cytotoxic drugs are dosed using body surface area (BSA), yet not all cancer patients receive the full BSA-determined dose. Prior work suggests that breast cancer patients who are obese are more likely to experience dose reduction than normal weight patients. However, the factors driving dose reduction remain unclear. METHODS In 452 women diagnosed with stage I-IIIA primary breast cancer
-
Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-11-04 M Gaudio,F Jacobs,C Benvenuti,G Saltalamacchia,R Gerosa,R De Sanctis,A Santoro,A Zambelli
PURPOSE HER2-low breast cancer (BC) is a novel entity with relevant therapeutic implications, especially in hormone receptor (HR) positive BC. This study examines whether HER2 mRNA through the 21-gene assay, Oncotype DX (ODX), can refine the diagnosis of HER2-low and HER2-zero, obtained by immunohistochemistry (IHC). METHODS Between Jan 2021 and Jan 2023, 229 consecutive HR-positive HER2-negative early
-
Racial/ethnic disparities in the association between patient care experiences and receipt of initial surgical breast cancer care: findings from SEER-CAHPS. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-31 Mariana Arevalo,Trevor A Pickering,Sally W Vernon,Kayo Fujimoto,Melissa F Peskin,Albert J Farias
PURPOSE We determined whether racial/ethnic differences in patient experiences with care influence timeliness and type of initial surgical breast cancer treatment for a sample of female Medicare cancer patients. METHODS We conducted a retrospective cohort study using the linked Epidemiology and End Results-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) dataset. The outcomes were:
-
Vaccination against COVID-19 reduced the mortality risk of COVID-positive hip fracture patients to baseline levels: the nationwide data-linked IMPACT Protect study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-28 Andrew J. Hall, N. D. Clement, A. M. J. MacLullich, T. O. White, A. D. Duckworth
Summary This nationwide study used data-linked records to assess the effect of COVID-19 vaccination among hip fracture patients. Vaccination was associated with a lower risk of contracting COVID-19 and, among COVID-positive patients, it reduced the mortality risk to that of COVID-negative patients. This provides essential data for future communicable disease outbreaks. Purpose COVID-19 confers a three-fold
-
Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-30 Joanne L Blum,Caroline DiCristo,David Gordon,Meghan S Karuturi,David Oubre,Erin Jepsen,Juan Cuevas,Shailendra Lakhanpal,Monica Z Montelongo,Zhe Zhang,Joseph C Cappelleri,Yao Wang,Debu Tripathy
PURPOSE Data on treatments for male breast cancer patients are limited owing to rarity and underrepresentation in clinical trials. The real-world POLARIS study gathers data on palbociclib use for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in female and male patients. This sub-analysis describes real-world palbociclib
-
Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-30 Sohee Park,Changhoon Choi,Haeyoung Kim,Yong Jae Shin,Yunjeong Oh,Won Park,Won Kyung Cho,Nalee Kim
PURPOSE This study aimed to compare the radiosensitizing effect of the PARP inhibitor, Olaparib, between proton and X-rays irradiations in BRCA-proficient breast cancer (BC) cells. METHODS Two BRCA-proficient BC cell lines, MDA-MB-231 and T47D BC, were used. Cell proliferation was assessed using the CCK-8 assay, and radiosensitivity was determined through the clonogenic survival assay. Flow cytometry
-
Screening mammographic performance by race and age in the National Mammography Database: 29,479,665 screening mammograms from 13,181,241 women. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-28 Cindy S Lee,Lenka Goldman,Lars J Grimm,Ivy Xinyue Liu,Michael Simanowith,Robert Rosenberg,Margarita Zuley,Linda Moy
PURPOSE There are insufficient large-scale studies comparing the performance of screening mammography in women of different races. This study aims to compare the screening performance metrics across racial and age groups in the National Mammography Database (NMD). METHODS All screening mammograms performed between January 1, 2008, and December 31, 2021, in women aged 30-100 years from 746 mammography
-
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-28 Yuan-Yuan Zhao,Hui-Juan Ge,Wen-Tao Yang,Zhi-Ming Shao,Shuang Hao
PURPOSE Secretory breast carcinoma is a rare histological subtype of invasive breast cancer and considered with an indolent clinical behavior. This study was conducted to analyze the clinicopathological features of patients with secretory breast carcinoma (SBC), explore the outcome, and compare the prognostic difference with invasive ductal breast carcinoma (IDC). METHODS AND MATERIALS: Patients with
-
Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States. Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-28 Hsiao-Ching Huang,Jenny S Guadamuz,Kent F Hoskins,Naomi Y Ko,Gregory S Calip
PURPOSE While breast cancer studies often aggregate Asian/Pacific Islander (API) women, as a single group or exclude them, this population is heterogeneous in terms of genetic background, environmental exposures, and health-related behaviors, potentially resulting in different cancer outcomes. Our purpose was to evaluate risks of contralateral breast cancer (CBC) among subgroups of API women with breast
-
Performance of FRAX in older adults with frailty: the Framingham Heart Study Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-24 Tanchanok Chattaris, Laiji Yang, Helena Johansson, Shivani Sahni, Elizabeth J. Samelson, Douglas P. Kiel, Sarah D. Berry
-
Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials Breast Cancer Res. Treat. (IF 3.8) Pub Date : 2023-10-25 Ratchanon Inpan, Mingkwan Na Takuathung, Wannachai Sakuludomkan, Nahathai Dukaew, Supanimit Teekachunhatean, Nut Koonrungsesomboon